GNOM News and Press, Global X Genomics & Biotechnology ETF From 12/26/20

Recent positive developments in COVID-19 vaccines have spurred a wave of market exuberance, lifting share prices of biotech companies at the forefront of the vaccine race. COVID-19 and the urgency to find a cure have opened up opportunities, making the biotech sector a prospective spa...

A broad and diverse effort is underway by biotech companies to solve the terrible riddle of the Coronavirus. Firms are forging ahead with testing, treatment and vaccine research and product development. Results of even the most promising treatments, however, are not yet clear cut....

Sandwiched between the two extremes of the largely shut-down Stay-at-Home Economy and a fully opened New Normal Economy, the Re-Opening Economy is an uncertain, transitional phase. We have identified multiple themes that we believe play an essential role in achieving these goals, incl...

Editors' Note: This is the transcript of the podcast we posted on July 30, 2020. Please note that due to time and audio constraints, transcription may not be perfect. We encourage you to listen to the podcast, embedded below, if you need any clarification. We hope you enjoy. Sig...

Sign up for Let's Talk ETFs on your favorite podcast platform: Apple Podcasts Spotify Google Play Stitcher By Jonathan Liss Since its founding in 2008, Global X ETFs has long had a reputation as a niche fund issuer, rolling out some of the most creative str...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good way to enter th...

In early January, researchers identified an irregular, lethal pneumonia spreading through China as the disease we now know as COVID-19. Global efforts to identify, treat, and limit the spread of the disease mobilized unprecedented resources toward Genomics, a cutting-edge field of biology with...

By Wvan McCulloch, Portfolio Manager, Director of Equity Research, Franklin Equity Group, and Wendy Lam, Ph.D., Portfolio Manager and Research Analyst, Franklin Biotechnology Discovery Fund Innovation has always been a key driver for the biotechnology industry. Even in the midst of the CO...

In my last article titled “ ACADIA: The company perspectives in numbers ”, I described the demographic trends that the company is operating under, listed key near-term catalysts, and made an overview of the company’s development. However, in the comments to the article, I ...

By Ansh Chaudhary The ETF Deathwatch decreased in size in April. Twenty exchange-traded products ("ETPs") were added to the list, and 34 funds were removed. Twenty-five of those funds were removed due to increased health and nine were due to asset managers closing their funds. That so ma...